A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy.
factor V inhibitors
haemophilia
hem‐irAE
immune checkpoint inhibitors
Journal
Respirology case reports
ISSN: 2051-3380
Titre abrégé: Respirol Case Rep
Pays: United States
ID NLM: 101631052
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
received:
22
12
2023
accepted:
08
02
2024
medline:
15
2
2024
pubmed:
15
2
2024
entrez:
15
2
2024
Statut:
epublish
Résumé
A 73-year-old woman with lung adenocarcinoma (cT4N3M1a: Stage IVA) was treated with atezolizumab as the eighth line of therapy. Four weeks after the fourth dose of atezolizumab, the prothrombin time (PT) and activated thromboplastin time (APTT) were prolonged. Coagulation factor V (FV) activity was decreased, and FV inhibitors were observed. There was no history of PT or APTT prolongation or bleeding before the use of atezolizumab. Atezolizumab-induced coagulation FV inhibitor was diagnosed. After 2 weeks, the PT and APTT spontaneously normalized. FV activity improved and the FV inhibitors disappeared after 6 and 9 weeks, respectively.
Identifiants
pubmed: 38356863
doi: 10.1002/rcr2.1307
pii: RCR21307
pmc: PMC10866682
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e01307Informations de copyright
© 2024 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.
Déclaration de conflit d'intérêts
None declared.